High Circulating CXCL10, FLT3LG Levels May Predict Worse Survival in Osteosarcoma
In patients with osteosarcoma, high circulating levels of CXCL10 and FLT3LG may be predictors of worse survival.
In patients with osteosarcoma, high circulating levels of CXCL10 and FLT3LG may be predictors of worse survival, according to a study published in Cancer.1
Researchers led by Ricardo Flores, MD, used Luminex assays in order to measure cytokine/chemokine concentrations in blood samples of patients with osteosarcoma from a discovery cohort at the Texas Children's Hospital in Houston as well an independent validation cohort through the Children's Oncology Group. A multivariate model was constructed in order to stratify patients into risk groups upon validation of biomarkers.
In both examined cohorts, the researchers found that circulating concentrations of C-X-C motif chemokine ligand 10 (CXCL10), Fms-related tyrosine kinase 3 ligand (FLT3LG), interferon y (IFNG), and C-C motif chemokine ligand 4 (CCL4) were significantly associated with overall survival.
CXCL10 and FLT3LG were found to be independently associated with metastasis at diagnosis, and these factors were combined to develop a multivariate model that stratified patients into 4 distinct risk groups. Survival analysis demonstrated that 5-year overall survival rates were 77% for low-risk patients, 54% for intermediate-risk patients, 47% for high-risk patients, and 10% for very high-risk patients.
RELATED: Higher CD4 Counts, Lower RNA Values Linked With Higher NHL, Sarcoma Incidence
Five-year event free survival was 64% for low-risk patients, 47% for intermediate-risk patients, 27% for high-risk patients, and 0% for very high-risk patients.
- Flores RJ, Kelly AJ, Li Y, et al. A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG. Cancer. 2016 Aug 16. doi: 10.1002/cncr.30272. [Epub ahead of print]